Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables (2016 - 2026)

Myriad Genetics has reported Receivables over the past 16 years, most recently at $115.3 million for Q4 2025.

  • Quarterly Receivables fell 4.87% to $115.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $115.3 million through Dec 2025, down 4.87% year-over-year, with the annual reading at $115.3 million for FY2025, 4.87% down from the prior year.
  • Receivables was $115.3 million for Q4 2025 at Myriad Genetics, down from $118.0 million in the prior quarter.
  • Over five years, Receivables peaked at $137.0 million in Q2 2025 and troughed at $91.3 million in Q4 2021.
  • The 5-year median for Receivables is $114.8 million (2023), against an average of $111.3 million.
  • The largest YoY upside for Receivables was 33.52% in 2021 against a maximum downside of 8.1% in 2021.
  • A 5-year view of Receivables shows it stood at $91.3 million in 2021, then increased by 11.28% to $101.6 million in 2022, then grew by 12.5% to $114.3 million in 2023, then grew by 6.04% to $121.2 million in 2024, then decreased by 4.87% to $115.3 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Receivables are $115.3 million (Q4 2025), $118.0 million (Q3 2025), and $137.0 million (Q2 2025).